Upadacitinib for the Management of Atopic Dermatitis in Patients Aged ≥60 Years: A Long-Term Multicenter Real-World Study.
BACKGROUND Atopic dermatitis (AD) in the elderly is increasing worldwide and presents therapeutic challenges due to age-related comorbidities that often contraindicate systemic therapies. Although oral Janus kinase (JAK) inhibitors show efficacy in moderate-to-severe AD, older adult patients are underrepresented in cli...